NYSE: ANVSAnnovis Bio Inc Stock
$1.22-0.04 (-3.17%)
Updated Apr 17, 2025
ANVS Price
$1.22
Fair Value Price
N/A
Market Cap
$23.77M
52 Week Low
$1.11
52 Week High
$20.00
P/E
-0.6x
P/B
2.55x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.5
Operating Cash Flow
-$22M
Beta
1.41
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ANVS Overview
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANVS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANVS
Ranked#448 of 463
Ranked#448 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important ANVS news, forecast changes, insider trades & much more!
ANVS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANVS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ANVS is good value based on its book value relative to its share price (2.55x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
ANVS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ANVS due diligence checks available for Premium users.
Valuation
ANVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
-177.72x
Market
27.98x
ANVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.55x
Industry
4.05x
ANVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANVS's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.9M
Profit Margin
0%
ANVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.9M
Liabilities
$4.6M
Debt to equity
0.5
ANVS's short-term assets ($13.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANVS's short-term assets ($13.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANVS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ANVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.3M
Investing
$0.0
Financing
$6.2M
ANVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANVS vs Biotech Stocks
Annovis Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.